Anna-Karin Haylock
Physician at Department of Surgical Sciences; Otorhinolaryngology and Head and Neck Surgery
- E-mail:
- anna-karin.haylock@uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 78/79
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 78/79
751 85 Uppsala
Publications
Recent publications
-
Part of Clinical Nutrition ESPEN, p. 149-155, 2020
- DOI for Mapping impact factors leading to the GLIM diagnosis of malnutrition in patients with head and neck cancer
- Download full text (pdf) of Mapping impact factors leading to the GLIM diagnosis of malnutrition in patients with head and neck cancer
-
Part of International Journal of Oncology, p. 1875-1885, 2018
- DOI for Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
- Download full text (pdf) of Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
-
Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
Part of Oncotarget, p. 65152-65170, 2017
- DOI for Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
- Download full text (pdf) of Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
-
Targeting molecules for diagnostics of Head and Neck squamous cell carcinoma
2017
-
A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties
Part of Nuclear Medicine and Biology, p. 12-18, 2016
All publications
Articles in journal
-
Part of Clinical Nutrition ESPEN, p. 149-155, 2020
- DOI for Mapping impact factors leading to the GLIM diagnosis of malnutrition in patients with head and neck cancer
- Download full text (pdf) of Mapping impact factors leading to the GLIM diagnosis of malnutrition in patients with head and neck cancer
-
Part of International Journal of Oncology, p. 1875-1885, 2018
- DOI for Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
- Download full text (pdf) of Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
-
Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
Part of Oncotarget, p. 65152-65170, 2017
- DOI for Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
- Download full text (pdf) of Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
-
A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties
Part of Nuclear Medicine and Biology, p. 12-18, 2016
-
Part of International journal of oncology, p. 461-470, 2016
- DOI for Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma
- Download full text (pdf) of Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma
-
A real-time in vitro assay as a potential predictor of in vivo tumour imaging properties
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2015
-
Part of EJNMMI Research, 2014
- DOI for In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study
- Download full text (pdf) of In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study
-
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014
-
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014
-
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2013
-
A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio
Part of International Journal of Oncology, p. 1525-1532, 2012
-
Part of Cancer Biotherapy and Radiopharmaceuticals, p. 593-601, 2011